Immuron Limited · ASX:IMC
Immuron — MarketOpen Direct Connect webinar (August 2024)
21 slides from Immuron's conference presentation, Aug 8, 2024
Slide 1: Immuron CEO webinar on MarketOpen Direct Connect
Immuron CEO, Steven Lydeamore webinar on MarketOpen Direct Connect Melbourne, Australia, August 8, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be hosting a webinar on MarketOpen Direct Connect on Thursday 8th August 2024, 11:
Slide 2: Immuron platform technology and IMM-124E
representing a long-term traveller population, are particularly affected given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012). Diarrhea is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces,
Slide 3: References and forward-looking statements
References Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012. Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium diff
Slide 4: Direct Connect Webinar - Steven Lydeamore
NASDAQ: IMRN ASX: IMC For personal use only Direct Connect Webinar Steven Lydeamore Chief Executive Officer 8 AUGUST 2024
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s For personal use onl
Slide 6: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only Company Overview Financial Snapshot Two commercially available
Slide 7: Addressable market & industry overview
Addressable market & industry overview Billion Dollar Market For personal use only Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent Symptom 30% - 70% of travelers experience traveller’s
Slide 8: Technology platform
Technology platform Immuron’s proprietary technology platform For personal use only combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and can b
Slide 9: Travelan Mechanism of action
Travelan® | Mechanism of action Pre-Clinical Studies For personal use only Broad spectrum antimicrobial Protects against bacterial Binds to surface layer proteins Toxin neutralization and adhesion to host cell intestinal preventing bacterial clearance of targeted gut epithelia colonization and motil
Slide 10: IMM-124E (Travelan) Phase 2 additional data analysis
IMM-124E (Travelan®) Phase 2 Study Additional data analysis Protective Efficacy For personal use only • Further analysis of the Phase 2 Study found that some subjects did not experience any diarrhoea until after antibiotics were administered • Diarrhoea could be related to antibiotic administration
Slide 11: Subjects with diarrhea of any severity
SUBJECTS WITH DIARRHEA OF ANY SEVERITY Intent-to-treat Analysis Set Travelan® (N=30) Placebo (N=30) Number of subjects with ETEC-induced diarrhoea of any severity [1] 13 (43.3%) 16 (53.3%) For personal use only P-value 0.438 95% 2-sided Confidence Interval (-15.2%, 35.2%) PE for a 5-Day Period Post
Slide 12: IMM-124E (Travelan): Kaplan-Meier Plot
IMM-124E (Travelan®): Kaplan-Meier Plot Conclusion: Plot Interpretation: o X-Axis: Time to onset of diarrhoea (e.g., days). In the clinical trial, the Kaplan-Meier plot shows o Y-Axis: Probability of remaining diarrhoea-free (survival probability). For personal use only that the Travelan® therapeuti
Slide 13: Time to diarrhoea onset
TIME TO DIARRHOEA ONSET • The Kaplan-Meier estimator is useful for For personal use only determining the time of the onset of diarrhoea Time to Diarrhea onset between patients receiving Travelan® or placebo treatment • Y-Axis: Probability of remaining diarrhoea-free • X-Axis: Time to onset of diarrh
Slide 14: IMM-124E (Travelan) adverse events
IMM-124E (Travelan®) Phase 2 Study – additional data analysis Adverse Events For personal use only • Includes all safety data set (63 subjects) and additional 3 subjects who were not challenged • Considers all Adverse Events and number of events over the whole study period pre and post challenge • N
Slide 15: Summary of adverse events
SUMMARY OF ADVERSE EVENTS Subjects with at least 1 AE per Travelan (N=32) Placebo (N=31) Reduction in System organ class Subjects Events Subjects Events number of Includes all safety data set (63 subjects) n (m) n (m) Events % For personal use only Total 24 58 28 109 46.8% (75%) (90.3%) Gastrointest
Slide 16: Summary of enrolled participants and demographics
IMM-124E (Travelan®) Phase 2 Study – additional data analysis Summary of Enrolled Participants For personal use only and Demographics 13
Slide 17: All enrolled subjects
ALL ENROLLED SUBJECTS For personal use only Travelan® (N=32) Placebo (N=31) Total (N=63) Randomization 32 31 63 Included in Safety Analysis Set 32 31 63 Intent-to-Treat Analysis Set 30 30 60 Completed Study 27 27 54 Discontinued Study 5 4 9 Subject Withdrew Consent 3 3 6 Investigator Discretion 2 0
Slide 18: Demographics
DEMOGRAPHICS Travelan® (N=32) Placebo (N=31) Total (N=63) For personal use only Mean Age at Consent 33.1 35.1 34.1 Sex at Birth Male 18 16 34 Female 14 15 29 Ethnicity Hispanic/Latino 5 10 15 Not Hispanic/Latino 27 21 48 Race White 8 (25%) 5 (16.1%) 13 (20.6%) Black or African American 23 (71.9%) 22
Slide 19: IMM-124E Phase 3 strategy
IMM-124E Phase 3 strategy Pre 2H 2024 1H 2025 2H 2025 Post For personal use only Phase 1 clinical study Additional topline data FDA meeting – Phase 3 Initiate Phase 3 Trial duration ~ 2 years (Baltimore, 1996) analysis August 2024 clinical protocol End of Phase 3 FDA meeting Phase 2 clinical study C
Slide 20: Steven Lydeamore contact information
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172
Slide 21: Scientific references
Scientific references Travelan® (IMM-124E) For personal use only Travelan® has been shown to reduce both the incidence and severity of ETEC- Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 induced diarrhea in up to 90% of volunteers Clinical Evaluation of
Immuron — MarketOpen Direct Connect webinar (August 2024) on 6ix